Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.78 USD

73.78
5,148,046

-0.56 (-0.75%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sweta Killa headshot

Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy

With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.

Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know

Gilead Sciences (GILD) closed at $66.92 in the latest trading session, marking a -0.03% move from the prior day.

Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

Key highlights of the past week include collaborations and other pipeline updates.

Company News for Jul 16, 2019

Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT

Gilead-Galapagos Ink $5.1B Deal for Additional Compounds

Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.

Christopher Vargas headshot

Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play

The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $66.19 in the latest trading session, marking a -1.88% move from the prior day.

Court Ruling Topples Trump Order, No Price Display in TV Ads

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Nilanjan Banerjee headshot

Will Patent Woes Boost Pharma Stock Megamergers Further?

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status

Glaxo's (GSK) long-acting, injectable two-drug regimen gets FDA's priority review designation. The company begins study to identify approaches to implementing once-monthly injectable HIV treatment in the real world.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed at $69 in the latest trading session, marking a +0.23% move from the prior day.

Gilead to Submit NDA for Inflammation Drug Filgotinib in '19

Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.

Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation

Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?

Alexion Receives FDA Approval for Label Expansion of Soliris

Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $67.08 in the latest trading session, marking a +0.6% move from the prior day.

Zacks Market Edge Highlights: Facebook, Gilead, Disney, Grubhub and Microsoft

Zacks Market Edge Highlights: Facebook, Gilead, Disney, Grubhub and Microsoft

Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion

Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.

Tracey Ryniec headshot

5 Game Changing M&A Deals of the Last Decade

M&A deals are usually ignored, or sometimes even openly mocked, but it can lead to an earnings and revenue renaissance. Did you spot these?

Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $69.38 in the latest trading session, marking a +1.18% move from the prior day.